Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself. - 2An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- 3Shrapnel hits across central Israel, injuring several, causing property damage
- 4What's A Decent FICO rating?
- 5This country music star spent years hiding his sexuality. Coming out — and beating addiction — has made his soul feel '20 pounds lighter.'
- Flu cases skyrocket in US. See cases, where people got sick.
- In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
- Five held on suspicion of planning attack on German Christmas market
- 6 Methods for further developing Rest Quality
- Miley Cyrus details her fear of paper, says fiancé Maxx Morando opens their packages outside: 'That's really why I got engaged'
- 4 Famous Gaming PCs of 2024: Execution, Versatility, and Advancement
- Inconceivable Spots To Stargaze All over The Planet
- Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- Indian rocket launches record-breaking BlueBird 6 smartphone satellite to orbit (video)
